ArticleBMC cancer2016

Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.

Kuo-Hsing Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.